Mirum Pharmaceuticals (MIRM) director granted options and 1,980 deferred stock units
Rhea-AI Filing Summary
Mirum Pharmaceuticals director Laura Brege reported equity awards consisting of deferred stock units and stock options. She received 1,980 deferred stock units, each representing a contingent right to one share of common stock, and 3,772 stock options to buy common stock at an exercise price of $101.00 per share.
Both the options and deferred stock units vest on the first anniversary of the June 15, 2026 grant date, and in any case will be fully vested by the company’s 2027 annual stockholder meeting. The options expire on June 14, 2036. Vested deferred stock units will be settled in common stock upon a change in control of Mirum or within 60 days after Brege’s separation from service.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Brege Laura
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 3,772 | $0.00 | $0.00 |
| Grant/Award | Deferred Stock Units | 1,980 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 3,772 shares (Direct);
Deferred Stock Units — 1,980 shares (Direct)
Footnotes (2)
- F1. The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting.
- F2. Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer.
Key Figures
Deferred stock units granted: 1,980 units
Stock options granted: 3,772 options
Option exercise price: $101.00 per share
+3 more
6 metrics
Deferred stock units granted
1,980 units
Grant to director Laura Brege on June 15, 2026
Stock options granted
3,772 options
Director award on June 15, 2026
Option exercise price
$101.00 per share
Stock Option (right to buy) grant
Option expiration date
June 14, 2036
Mirum stock options issued to director
Underlying shares for DSUs
1,980 shares
Each deferred stock unit equals one common share
Underlying shares for options
3,772 shares
Stock options for Mirum common stock
Key Terms
Deferred Stock Units, Stock Option (right to buy), exercise price, change in control, +1 more
5 terms
Deferred Stock Units financial
"Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock"
Deferred stock units are promises from a company to give an employee shares of stock at a future date, often after certain conditions are met or after leaving the company. They function like a form of delayed compensation, allowing employees to earn shares over time. For investors, they represent potential future ownership in the company, but do not provide immediate voting rights or dividends until the shares are actually received.
Stock Option (right to buy) financial
"Stock Option (right to buy) with an exercise price of 101.0000"
exercise price financial
"conversion_or_exercise_price": "101.0000""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
change in control financial
"paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
separation from service financial
"within 60 days following separation from service with the Issuer"
FAQ
What insider transactions did Mirum Pharmaceuticals (MIRM) report for Laura Brege?
Mirum reported that director Laura Brege received equity awards on June 15, 2026. She was granted 1,980 deferred stock units and 3,772 stock options, both tied to Mirum common stock as part of her director compensation package.
How many stock options did Laura Brege receive from Mirum Pharmaceuticals (MIRM) and at what price?
Laura Brege received 3,772 stock options from Mirum Pharmaceuticals. Each option allows her to buy one share of Mirum common stock at an exercise price of $101.00 per share, with the options expiring on June 14, 2036.
When do Laura Brege’s Mirum (MIRM) stock options and deferred stock units vest?
Both the 3,772 stock options and 1,980 deferred stock units vest on the first anniversary of the June 15, 2026 grant date. They will in any case be fully vested by the date of Mirum’s 2027 annual stockholder meeting.
What are deferred stock units in Mirum Pharmaceuticals (MIRM) Form 4 for Laura Brege?
Deferred stock units are rights to receive Mirum common shares in the future. Brege’s 1,980 units each convert into one share, vest after one year, and are paid in stock upon a change in control or within 60 days after her separation from service.
AI-generated analysis. How Rhea-AI works. Not financial advice.
